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lipoproteins, lowers LDL-cholesterol on average by 28%. This com-
pound, mipomersen, is injected weekly subcutaneously.
A second agent that inhibits the formation of apoB-containing 
lipoproteins in liver and gut is an inhibitor of microsomal triglyceride 
transfer protein (MTP). This compound lowered LDL-cholesterol by 
50% in patients with homozygous familial hypercholesterolemia. 
A side effect of both classes of drugs is the accumulation of fat in 
the liver.
Proprotein convertase subtilisin/kexin type 9 serine protease 
(PCSK9) is a protease that induces degradation of LDL-receptors. 
Statins increase the concentration of PCSK9, thereby attenuating 
their LDL-cholesterol–lowering effect. Combining statins with inhibi-
tors of PCSK9 has proven to be very effective in LDL-cholesterol 
lowering: injection of monoclonal antibodies to PCSK9 biweekly 
on top of maximal statin therapy lowered LDL-cholesterol by an 
extra 60%. If long-term treatment with these antibodies proves to 
be safe, this will change the treatment of patients with severe familial 
hypercholesterolemia. The near future years will also provide the 
final verdict whether raising HDL-cholesterol by means of inhibition 
of cholesteryl ester transfer protein (CETP) will be of any benefit.
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Summary: Tumor necrosis factor-alpha (TNF-alpha) plays a role in 
the process of intraocular inflammation that is the cause that the use 
of TNF-alpha inhibitor agents is worldwide spread to treat differ-
ent form of intraocular inflammations. In ophthalmology, anti-TNFs 
are applied in the treatment of uveitis and immune-vasculitis. The 
number of TNF-alpha inhibitors is increasing despite the fact that 
such kind of medication can be used “off-label” in the treatment 
of inflammations. TNF-alpha inhibitors are effective at first in that 
form of uveitis that is connected with systemic immunologic diseases: 
Mo. Behcet, rheumatoid arthritis (especially with juvenile idiopathic 
arthritis), Mo. Chrohn, Wegener granulomatosis, autoimmune dis-
eases (lupus-like syndrome [LLS]). In cases of vasculitis, it can be 
used in giant cell arthritis, Takayasu arthritis, primary angiitis of the 
central nervous system, and Cogan syndrome. Anti–TNF-alpha also 
are effective in cases of autoimmune, noninfectious diseases of the 
eye: Mo. Harada, sympathetic ophthalmia. The most frequent anti–
TNF-alpha that are used are etanercept, adalimumab, and infliximab. 
There are 3 other TNF-alpha inhibitors that are less widespread yet: 
golimumab, certolizumab, and tocilizumab. The advantage of the 
TNF-alpha inhibitors are that they have fewer side effects as corti-
costeroids and immunsuppressives but are more effective. Their only 
disadvantage: they are very expensive.
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Summary: With the increasing needs for better outcome, func-
tion, and quality of life in arthritides and autoimmune diseases, we 
have increasing amounts of information on the major pathogenetic 
pathways underlying rheumatoid arthritis (RA), spondyloarthriti-
des (SpA), lupus, scleroderma, and other rheumatic diseases. After 
decades of reliance on largely empiric approaches in the therapy 
of most of these diseases, the introduction of TNF-alpha–blocking 
agents in the late 1990s revolutionized the therapy of rheumatoid 
arthritis (RA), other arthritides, and connective tissue diseases. 
Numerous pathways have been targeted and almost 10 biologics 
have been registered to treat RA, SpA, and lupus. In addition to 
anti-TNF biologics, further therapies such as anti–IL-6R, CTLA4-
inhibitor, or anti-CD20 agents along with several new experimental 
approaches have since emerged out of improved understanding of 
the immunopathogenesis. In addition to biologics, the first small 
molecular targeted therapies, mostly tyrosine kinase inhibitors, have 
been developed. Most therapies primarily intended for RA, however, 
have failed to show or have shown only marginal benefit in other 
autoimmune rheumatic diseases such as lupus, scleroderma, poly-
myositis, or vasculitides, all of which continue to have a high unmet 
medical need. Challenges to identify novel drug candidates and to 
conduct successful clinical studies for such diseases include the dif-
ferent and highly complex immunopathology as well as clinical 
trial–related issues (eg, the lack of validated, sensitive, and reliable 
end points). Recently, promising new therapeutic approaches have 
emerged. This presentation highlights these advances in autoimmune 
rheumatic diseases.
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Summary: In the last decades, both regulators and manufactur-
ers have used computerized data-mining techniques on reports 
of adverse drug reactions from both health care practitioners and 
consumers to detect drug safety signals, that is, unknown or incom-
pletely documented drug-event associations. The signal detection 
using data from spontaneous reporting system (SRS) databases is 
negatively influenced however by under- and selective reporting as 
well as missing denominators. To overcome some of these shortcom-
ings, in the last 5 years, a number of ongoing international initia-
tives (Sentinel, Protect, OMOP, EU-ADR) has started to explore 
longitudinal observational health care data, including electronic 
health records (EHRs), as an additional source for signal detec-
tion. The ultimate goal of the EU-ADR project was to develop an 
innovative, computerized system for the automatic detection of drug 
safety signals. Using a database network of 7 databases from 3 coun-
tries covering ~30 million European patients, EU-ADR developed 
new methodologies for signal detection and compared the perfor-
mance (both in terms of precision and timing) of signal detection 
using either EHRs or SRS through validation sets. Main findings 
of the project are that EU-ADR is not powered enough to monitor 
infrequently used/captured drugs and associations regarding very 
rare events, while SRS may be more efficient. On the other hand, 
EU-ADR has the most power for signal detection concerning events 
with higher incidences rate and not commonly reported to SRS. In 
this presentation, the overview of methodology and results from 
EU-ADR will be presented and the potentially additional value of 
exploring EHRs in the context of pharmacovigilance will be dis-
cussed.
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